Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05436639 · ClinicalTrials.gov registry record · Phase 2
SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor
A Phase 2 study, sponsored by Sparrow Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT05436639 is a Phase 2 study that has completed, run by Sparrow Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT05436639, a Phase 2 study, has completed, sponsored by Sparrow Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is study with SPI-62 to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor. Each subject will receive 2mg of SPI-62 daily.
Interventions
- DRUG SPI-62 dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-07-01 |
| Est. Completion | 2025-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05436639
The ClinicalTrials.gov registry entry for NCT05436639 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sparrow Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SPI-62 dose is the first listed.
NCT05436639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05436639 about?
NCT05436639 is a clinical study titled "SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor". This is study with SPI-62 to evaluate the efficacy, safety, and pharmacological effect of SPI-62 in subjects with hypercortisolism related to a benign adrenal tumor. Each subject will receive 2mg of SPI-62 daily.
What is the current status of trial NCT05436639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-07-01. Estimated completion is 2025-02-18.
What interventions are being tested in trial NCT05436639?
The interventions under investigation include: SPI-62 dose (DRUG).
Who is sponsoring clinical trial NCT05436639?
This trial is sponsored by Sparrow Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.